All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
2023-01-24T12:56:25.000Z

Zanubrutinib receives FDA approval for CLL and SLL

Jan 24, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic lymphocytic leukemia.

On January 19, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had granted approval to zanubrutinib, a Bruton’s tyrosine kinase inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1

The approval is based on key data obtained from the SEQUOIA trial (NCT03336333), which compared zanubrutinib with bendamustine + rituximab in patients with previously untreated CLL or SLL, and the ALPINE trial (NCT03734016), which compared zanubrutinib with ibrutinib in patients with relapsed or refractory (R/R) CLL or SLL.

Both trials demonstrated improved efficacy and an acceptable safety profile for zanubrutinib in CLL/SLL.

  • In the SEQUOIA trial, zanubrutinib showed a significant progression-free survival benefit versus bendamustine + rituximab
  • In the ALPINE trial, zanubrutinib demonstrated a superior overall response rate compared with ibrutinib in R/R patients
  • The overall safety profile of zanubrutinib therapy was consistent with previous studies in both trials

  1.  BRUKINSA® Approved in the U.S. for chronic lymphocytic leukemia. https://www.businesswire.com/news/home/20230119005888/en/BRUKINSA%C2%AE-Approved-in-the-U.S.-for-Chronic-Lymphocytic-Leukemia. Published Jan 19, 2023. Accessed Jan 20, 2023.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you